Table 3.
The changes in CGH management outcomes in experimental and control groups vs time.
| Pre treatment | Post treatment | 1-year follow up | 2-year follow up |
P |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G | T | G Vs t | ||||||||||
| Frequency | E | 11.7 ± 1.4 | 6.2 ± 1.6 [ 3.7] | 1.3 ± 1 [ 8.5 ] | 1.2 ± 1.3 [7.7 ] | <0.001∗ | <0.001∗ | <0.001∗ | ||||
| C | 12 ± 1.5 | 5.7 ± .9 [5.09 ] | 7.6 ± .9 [ 3.5 ] | 9.1 ± 1 [2.2 ] | ||||||||
| .07 [-0.04 1.09] | <0.001∗ [-6.7–5.9] | <0.001∗ [-8.3 -7.38] | ||||||||||
| HDI | E | 78.8 ± 7.4 | 45.8 ± 4.1 [ 5.5 ] | 19.3 ± 7.1 [8.2 ] | 15.6 ± 8.2 [8.09 ] | <0.001∗ | <0.001∗ | <0.001∗ | ||||
| C | 79.9 ± 6.4 | 47.8 ± 6.1 [ 5.1 ] | 67.4 ± 9.4 [1.5] | 67.3 ± 9.4 [ 1.5] | ||||||||
| .07 [-4.4 .2] | <0.001∗ [-51.7–44.4] | <0.001∗ [-55.6–47.8] | ||||||||||
| HIT-6 | E | 65.8 ± 5.7 | 46.3 ± 5 [ 3.6 ] | 38.5 ± 2.2 [6.3 ] | 37.1 ± 1.9 [ 6.7] | <0.001∗ | <0.001∗ | <0.001∗ | ||||
| C | 70.1 ± 4.7 | 47.4 ± 3.2 [ 5.6 ] | 51.8 ± 4.3 [4] | 65.4 ± 4.7 [1] | ||||||||
| .2 [-2.8 0.8] | <0.001∗ [-14.7–11.7] | <0.001∗ [-29.9–26.7] | ||||||||||
| DDD | E | .57 ± .14 | .34 ± .07 [2.07 ] | .059 ± .06 [4.7 ] | .03 ± .04 [5.2 ] | <0.001∗ | <0.001∗ | <0.001∗ | ||||
| C | .58 ± .12 | .31 ± .1 [2.4 ] | .52 ± .12 [ .5 ] | .57 ± .11 [0.08 ] | ||||||||
| .3 [-0.03 0.07] | <0.001∗ [-0.5–0.41] | <0.001∗ [-0.61–0.50] | ||||||||||
Data are given as mean (sd) [effect size]. E: experimental group C: control group HDI: Headache disability inventory HIT-6: headache impact test-6 DDD: Daily defined dose G: group T: time G vs T: group versus time.
∗ indicates statistically significant difference.